Royalty Pharma plc (RPRX) Stock

Royalty Pharma plc (RPRX) is a Healthcare stock trading at $61.30 (as of 2026-08-21), with a market capitalization of $34.13B and a trailing P/E of 41.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Royalty Pharma plc buys biopharmaceutical royalty interests and provides funding for biopharmaceutical innovation. It identifies, evaluates, and acquires royalties tied to marketed therapies and development-stage product candidates, working with entities such as academic institutions, research hospitals, and biopharma companies in the United States.

Understand Royalty Pharma plc: how it makes money

Royalty Pharma buys and acquires biopharmaceutical royalties, evaluates and funds innovations in the biopharmaceutical industry, and collaborates with research and healthcare innovators, earning from a portfolio of royalties on marketed therapies and development-stage product candidates.

Its profit model is built around owning royalties on a portfolio of biopharmaceutical therapies, where returns depend on those therapies generating royalty streams over time.

Business quality (Strong): Clear business model as a royalty buyer and funder of biopharmaceutical innovation, but the provided facts do not include segment breakdowns or operating KPIs to track day to day performance.

Valuation: At 30× earnings, RPRX trades 76% above the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

  • Portfolio of royalties across marketed and development-stage therapies: The company’s portfolio includes royalties on approximately 35 marketed therapies and 10 development-stage product candidates.
  • Ongoing deal sourcing capability: It is involved in the identification, evaluation, and acquisition of royalties on biopharmaceutical therapies, and it collaborates with innovators across academia, research hospitals, not-for-profits, biotech companies, and pharmaceutical companies.

Bear case

  • Royalty performance dependence: Because the model centers on owning royalties, outcomes can be sensitive to the commercial performance and durability of the underlying marketed therapies.
  • Execution and timing uncertainty in development-stage candidates: Returns from development-stage product candidates depend on those candidates progressing and becoming marketed therapies, which can introduce timing uncertainty.
Valuation — source: SEC EDGAR (first-party)
Price$61.30
Market Cap$34.13B
P/E Ratio41.3
EV / EBITDA26.7
Price / Book3.43
Price / Sales13.99
DCF Value (model)$119.35
DCF Upside vs Price94.7%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.38B
Net Margin32.4%
Revenue Growth (YoY)11.0%
EPS Growth (YoY)21.8%
Financial Health — source: SEC EDGAR
Altman Z-Score2.70 (grey)
Valuation vs Sector & Industry
Stock P/E41.3
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
vs Sector89.8%
vs Industry140.2%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderMORGAN STANLEY ($2.09B)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOPablo Legorreta
Employees75
CountryUS
IPO Date2020-06-16

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

  • Sarepta Therapeutics, Inc. (SRPT)
  • BioMarin Pharmaceutical Inc. (BMRN)
  • Alnylam Pharmaceuticals, Inc. (ALNY)
  • Phibro Animal Health Corporation (PAHC)
  • Elanco Animal Health Incorporated (ELAN)
  • Lakefront Biotherapeutics NV (LKFT)
  • Prestige Consumer Healthcare Inc. (PBH)
  • Madrigal Pharmaceuticals, Inc. (MDGL)
RPRX earnings history · RPRX institutional & insider holders · RPRX KPIs & operating metrics · RPRX financials · RPRX investor presentations & press releases · RPRX SEC filings · RPRX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.